Compare Eli Lilly And Co (LLY) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Alliant Energy Corporation — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Alliant Energy Corporation trades at $65.85 (market cap $16.99B). The key difference: Eli Lilly And Co is far larger — about 61.2× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Alliant Energy Corporation for 64 Days on average.
| LLY | LNT | |
|---|---|---|
Market Cap | $1.04T | $16.99B |
Volume | 3,064,878 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $1.28K | $78.03 |
52-Week Low | $799.57 | $63.21 |
Typical Hold Time | 93 Days | 64 Days |
Enterprise Value | $1.09T | $29.08B |
Dividend Yield | 0.59% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
LNT trades at $65.85, up 0.98% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported 2025 revenue of $4.36B and net income of $810M, with a net margin of 18.56%. A $13.4B capital investment plan supports long-term growth, while analyst consensus is a Buy with a $77.00 price target, implying significant upside from current levels.
Outlook remains positive due to steady utility demand and data center growth, but risks include rising debt levels and cost pressures. The stock offers a defensive profile with a 23-year dividend growth history, though valuation multiples like a P/E of 20.74 require sustained earnings expansion to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
